Opinion|Videos|August 16, 2024
Personalizing Treatment Selection
A key opinion leader in dermatology explains how the presence of type 2 inflammation informs their treatment decisions for atopic dermatitis and prurigo nodularis, while also detailing additional patient-specific factors such as age, comorbidities, and disease severity that influence their therapeutic approach.
Episodes in this series
- How does knowing that type 2 inflammation is a cause influence your treatment selection?
- Beyond identifying the underlying cause, what other patient-specific factors (e.g., age, comorbidities, disease severity) do you consider when selecting treatment regimens for AD or PN?
Related to this article
Machine learning identified age, BMI, income, and reproductive factors as key predictors of overactive bladder risk among US women.
Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
Clinicians pair CD20×CD3 bispecifics with radiotherapy in relapsed B‑cell lymphoma, but data stay sparse—early safety signals prompt trials.
Panelists at NASP inSPire2026 said specialty pharmacies could close clinical trial enrollment gaps by capturing one missed data point.
“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.
Across 29,132 surgically treated T1 cases, lymph node metastasis hit 19.2% under age 50 vs 11.1% at 50 and older.
Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.
Trending on AJMC
1
Surrogate End Points, Drug Costs Complicate Oncology Formularies
2
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
3
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
4
Medicare Part D Ruxolitinib Spending Hits $49.6 Million as Use Surges
5